Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Rhea-AI Summary

Dermata Therapeutics (Nasdaq: DRMA) has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 9-11, 2024. The event will be held at the Lotte New York Palace Hotel, with virtual participation options available. Gerry Proehl, Chairman, President, and CEO of Dermata, will present an overview of the company's business and provide an update on their Phase 3 acne program.

The conference will feature over 550 company presentations, available both live and on-demand. Investors interested in attending Dermata's presentation can register through the provided link. The company's virtual presentation will be available on-demand starting September 9 at 7:00 A.M. Eastern Time.

Positive

• Participation in a major investment conference, potentially increasing visibility to investors
• Opportunity to present updates on the company's Phase 3 acne program

Negative

• None.

SAN DIEGO, CA / ACCESSWIRE / September 5, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced it will be presenting at the H.C. Wainwright 26^th Annual Global Investment Conference, being held September 9-11, 2024.

The in-person venue for the event is the Lotte New York Palace Hotel in New York City located at
455 Madison Avenue. Virtual participation will be staged simultaneously with over 550 company presentations scheduled as live feed or available on-demand.

Gerry Proehl, Chairman, President, and Chief Executive Officer of Dermata, will provide an overview of the Company's business and an update on the Company's Phase 3 acne program during the presentation.

If you are an investor, and would like to listen to the Company's presentation, please click on the following link (www.hcwevents.com/annualconference) to register for the conference.

Over 550 corporate presentations and panels are available during September 9-11, 2024.

Event: H.C. Wainwright 26^th Annual Global Investment Conference
Date: September 9-11, 2024
Time: 7:00AM (Eastern Time)
Location: Virtual to start on-demand on September 9 at 7:00 A.M. (ET)

About Dermata Therapeutics

Dermata Therapeutics, Inc. is a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions. The Company's lead product candidate, DMT310, is the Company's first product candidate being developed from its Spongilla technology platform and is currently being evaluated in a Phase 3 program. DMT310 is a once-weekly topical product candidate derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action. DMT310 has been studied for the treatment of acne, rosacea, and psoriasis. The Company's second product candidate, DMT410, uses its Spongilla technology as a new method for topical intradermal delivery of botulinum toxin for the treatment of hyperhidrosis and multiple aesthetic skin conditions. Dermata is headquartered in San Diego, California. For more information, please visit http://www.dermatarx.com/.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company's current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other factors including, but are not limited to, statements related to: the potential development and commercialization of product candidates; the ability of the Company's product candidates to achieve applicable endpoints in clinical trials; whether the results of the Company's product candidates will lead to future product development; and whether the Company will have the ability to obtain adequate funding for future development of its product candidates. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug development, approval, and commercialization, and the fact that past results of clinical trials may not be indicative of future trial results. For a discussion of these and other factors, please refer to Dermata's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

About H.C. Wainwright & Co.

H.C. Wainwright is a full‐service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright's team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.

For more information visit H.C. Wainwright & Co. on the web at www.hcwco.com.

Investors:

Sean Proehl
Associate General Counsel
info@dermatarx.com

SOURCE: Dermata Therapeutics

View the original press release on accesswire.com

FAQ

When is Dermata Therapeutics (DRMA) presenting at the H.C. Wainwright Global Investment Conference?

Dermata Therapeutics (DRMA) will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference, which takes place from September 9-11, 2024. Their virtual presentation will be available on-demand starting September 9 at 7:00 A.M. Eastern Time.

What will Dermata Therapeutics (DRMA) discuss in their presentation at the H.C. Wainwright conference?

Gerry Proehl, Chairman, President, and CEO of Dermata Therapeutics (DRMA), will provide an overview of the company's business and an update on their Phase 3 acne program during the presentation at the H.C. Wainwright conference.

Where is the H.C. Wainwright 26th Annual Global Investment Conference being held?

The in-person venue for the H.C. Wainwright 26th Annual Global Investment Conference is the Lotte New York Palace Hotel in New York City, located at 455 Madison Avenue. There is also a virtual participation option available.

How can investors access Dermata Therapeutics' (DRMA) presentation at the H.C. Wainwright conference?

Investors interested in listening to Dermata Therapeutics' (DRMA) presentation can register for the conference through the provided link (www.hcwevents.com/annualconference). The virtual presentation will be available on-demand starting September 9, 2024, at 7:00 A.M. Eastern Time.